A Phase 1 interventional study of LTI-03 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Rein Therapeutics. Completed at 7 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Rein Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 144th largest by enrollment of the 188 interventional ones that give a count, is one of 14 that started in 2023, is one of 39 in phase 1, and was the 178th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Oorja Bio, Inc. · Sites in United States
Ages 40+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 85 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
Rein Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Rein Therapeutics has 2 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
This is a randomized, double-blind, placebo controlled, multi-center, dose escalation, safety and tolerability study of LTI-03 or placebo administered by inhalation in participants recently diagnosed with idiopathic pulmonary fibrosis that have not received prior treatment with anti-fibrotic agents.
The study will contain 2 dose cohorts which will run sequentially.
Eligible participants will be randomized in a 3:1 ratio to either LTI-03 or placebo. Safety data will be reviewed on an ongoing basis. Enrollment in the second cohort will not begin until the Cohort 1 safety data has been reviewed.
The Treatment Period will be 14 days, with subjects self-administering study drug using a provided commercially available dry-powder inhaler.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg LTI-03 BID x 14 days
Drug: LTI-03
5 mg LTI-03 BID x 14 days
Drug: LTI-03
Matching placebo BID x 14 days
Drug: Placebo
Caveolin-1-Scaffolding-Protein-Derived Peptide
Also known as: Micronized dry powder in hard 2 piece hypromellose capsules
Matching placebo
Also known as: Micronized lactose powder in capsule
Incidence of Treatment-emergent Adverse Events (TEAEs)
Incidence of TEAEs by dose
Time frame: 21 days (dosing x 14 days; follow up x 7 days)
| Milestone | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo |
|---|---|---|---|
| Started | 9 | 9 | 6 |
| Completed | 9 | 9 | 6 |
| Not completed | 0 | 0 | 0 |
Incidence of TEAEs by dose
| percentage of participants | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo |
|---|---|---|---|
| Any TEAE | 66.7 | 77.8 | 50.0 |
| Any TEAE with CTCAE severity Grade 3 or higher | 0 | 0 | 0 |
| Any study drug-related TEAE | 22.2 | 55.6 | 16.7 |
| Any TEAE leading to treatment discontinuation | 0 | 0 | 0 |
| Any serious TEAE | 0 | 11.1 | 0 |
| Any TEAE leading to death | 0 | 0 | 0 |
Collected over From ICF (if serious or related to protocol assessment) or Dosing Day 1 through End of Study Day 21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2.5 mg LTI-03 BID | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| 5 mg LTI-03 BID | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Event | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo |
|---|---|---|---|
| Post-procedural feverInjury, poisoning and procedural complications | 0/9 | 1/9 | 0/6 |
| Event | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 3/9 | 5/9 | 2/6 |
| DizzinessNervous system disorders | 0/9 | 0/9 | 1/6 |
| Esophageal spasmGastrointestinal disorders | 0/9 | 0/9 | 1/6 |
| PalpitationsCardiac disorders | 0/9 | 1/9 | 0/6 |
| DysgeusiaNervous system disorders | 1/9 | 0/9 | 0/6 |
| Ophthalmic migraineNervous system disorders | 1/9 | 0/9 | 0/6 |
| Chest discomfortGeneral disorders | 1/9 | 0/9 | 0/6 |
| FatigueGeneral disorders | 1/9 | 0/9 | 0/6 |
| VertigoEar and labyrinth disorders | 0/9 | 1/9 | 0/6 |
| Dry mouthGastrointestinal disorders | 0/9 | 1/9 | 0/6 |
| Age, Categorical(Participants) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 3 | 1 | 8 |
| >=65 years | 5 | 6 | 5 | 16 |
| Age, Continuous(years) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 67.8 ± 9.76 | 68.4 ± 10.79 | 71.7 ± 6.15 | 69.0 ± 9.19 |
| Sex: Female, Male(Participants) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 0 | 4 |
| Male | 7 | 7 | 6 | 20 |
| Ethnicity (NIH/OMB)(Participants) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 9 | 6 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 9 | 9 | 6 | 24 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| United States | 2 | 1 | 0 | 3 |
| United Kingdom | 3 | 2 | 3 | 8 |
| Germany | 3 | 4 | 2 | 10 |
| Australia | 1 | 2 | 1 | 3 |
| Height(cm) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 170.93 ± 9.270 | 169.56 ± 9.530 | 177.17 ± 7.111 | 171.98 ± 9.067 |
| Weight(kg) | 2.5 mg LTI-03 BID | 5 mg LTI-03 BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 84.49 ± 11.709 | 85.36 ± 25.108 | 91.45 ± 11.529 | 86.55 ± 17.446 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2023 to primary completion in Sep 2024, 14 months.
Results were first posted in Jul 2025, 10 months after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 14 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LTI-03
Idiopathic Pulmonary Fibrosis →
Rein Therapeutics